Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.1 USD | +0.37% | +2.86% | -12.00% |
May. 10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
May. 10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.00% | 91.1B | |
+29.49% | 684B | |
+30.34% | 568B | |
-4.01% | 361B | |
+17.66% | 329B | |
+4.20% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.13% | 166B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Earnings Flash (BMY) BRISTOL MYERS SQUIBB Posts Q4 Revenue $11.41B, vs. Street Est of $11.20B